RxDoctor Payments Data

Prema Abraham, MD

Retina Specialist · Rapid City, SDNPI 1063492940

Payments from drug & device makers

$5,104,945in general payments, 2019–2025

Across 687 payments — averaging $7430.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.6M
  • Bayer$645K
  • Ocular Therapeutix, Inc.$583K
  • Apellis Pharmaceuticals, Inc.$557K
  • Regeneron$539K
  • Roche TCRC, Inc.$509K
  • plus $666K from 21 others
$1,632in research payments, 2019–2025

Across 1 payment — averaging $1631.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$2K

What the payments were for

  • Consulting fees$2,21727%
  • Food & beverage$3,35141%
  • Ownership interest$2,63132%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$14,286,818
Medicare patients
1,792
Services billed
2,559,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate379$11,766
Ofloxacin231$2,761
CombiganBrimonidine Tartrate/Timolol14$2,547
Atropine Sulfate104$2,451
Difluprednate13$1,572
Ketorolac Tromethamine60$1,427
Acetazolamide ErAcetazolamide29$878
Acetazolamide15$717
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha32$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$41,568$2,54714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in South Dakotaon file to place this against a meaningful peer group, so we don't.

Other retina specialist in Rapid City

Where these figures come from

Is this you, or does something look wrong? →